Zealand Pharma sued over misusing trade secrets

Two separate joint ventures never materialized for Greek biotech company Amyndas, leaving it first to ponder why, and later to blame Zealand Pharma and its US affiliate for running away with its secrets.

Adam Steensberg was the interim CEO when Zealand Pharma signed a partnership deal with Alexion, which was also a breach of confidentiality agreements a Greek firm claims | Photo: Zealand Pharma

”When biotech firms engage in the entrepreneurial equivalent of musical chairs, one firm sometimes gets left out in the cold. That is essentially what happened here.”

Thus opens the appellate court’s decision, penned by Judge Selya of the US Court of Appeals for the First Circuit, in the matter of legal claims against Zealand Pharma concerning the misappropriation of trade secrets, the breaching of confidential disclosure agreements, and conspiracy with another firm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs